Chippenham, UK – 28 June 2017: Vectura Group plc (LSE: VEC) (“the Group”), an industry-leading inhaled airways disease focused business, is holding a Capital Markets Event for analysts and institutional investors today in London, starting at 13:00pm BST.
James Ward-Lilley, Chief Executive Officer, will host the event together with members of the Executive Leadership and senior management teams. In addition, Tim Harrison, Professor of Asthma and Respiratory Medicine at The Asthma Centre, Nottingham Respiratory Research Unit, and lead investigator for Vectura’s wholly owned pipeline candidate, VR475, will provide a clinical perspective on the Asthma and COPD landscape.
A live webcast of the event, with the presentation slides, will be available on Vectura’s website at: http://www.vectura.com/investors/presentations-webcasts/. No price sensitive information will be disclosed.
- ENDS -
For more enquiries, please contact
|Vectura Group plc
Fleur Wood – Director Communications
Elizabeth Knowles – Director Investor Relations and Analysis
|+44 (0)1249 667700|
|Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson
Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With our extensive range of device and formulation technologies, integrated capabilities and collaborations, we are a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.
Vectura has eight inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, and Tianjin KingYork. For further information, please visit Vectura's website at www.vectura.com.